List of Excipients in Branded Drug PERIDEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	PERIDEX	chlorhexidine gluconate	0116-0620	ALCOHOL
Xttrium Laboratories Inc	PERIDEX	chlorhexidine gluconate	0116-0620	FD&C BLUE NO. 1
Xttrium Laboratories Inc	PERIDEX	chlorhexidine gluconate	0116-0620	GLYCERIN
Xttrium Laboratories Inc	PERIDEX	chlorhexidine gluconate	0116-0620	SACCHARIN SODIUM

Peridex Excipient Strategy and Commercial Opportunities for Chlorhexidine Gluconate Oral Rinse

Last updated: August 8, 2026

Peridex is a 0.12% chlorhexidine gluconate prescription oral rinse used to reduce gingivitis. Its commercial position is based on clinical familiarity, dental-office adoption, and a relatively simple aqueous formulation rather than a strong remaining patent barrier. The main excipient opportunities are alcohol-free delivery, improved taste, lower staining perception, preservative reduction, unit-dose packaging, and differentiated professional-channel products.

What is the Peridex formulation and which excipients does it contain?

Peridex contains chlorhexidine gluconate equivalent to 0.12% chlorhexidine. The labeled inactive ingredients are water, alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No. 1.[1]

Component	Function in the formulation	Commercial or technical relevance
Water	Primary vehicle	Supports aqueous delivery and oral rinsing
Alcohol, approximately 11.6% v/v	Co-solvent and formulation aid	Contributes to sensory profile and creates alcohol-free differentiation opportunity
Glycerin	Humectant and mouthfeel modifier	Reduces harshness and improves lubrication
PEG-40 sorbitan diisostearate	Solubilizer and surfactant	Helps disperse flavor components and maintain formulation uniformity
Flavor	Taste masking	Important for adherence and dental-office acceptance
Sodium saccharin	High-intensity sweetener	Masks chlorhexidine bitterness
FD&C Blue No. 1	Colorant	Supports product identification but adds colorant-related formulation and labeling considerations

The formulation is not an extended-release system, nanoparticle product, liposomal product, or mucoadhesive dosage form. The principal technical challenge is maintaining chlorhexidine availability, antimicrobial performance, physical stability, and acceptable taste while changing the excipient system.

What is the FDA status of Peridex?

Peridex is an FDA-approved prescription oral rinse containing chlorhexidine gluconate 0.12%. The product is indicated for use between dental visits as part of a professional program for treatment of gingivitis, including reduction of gingival inflammation, redness, and bleeding.[1]

The label directs patients to rinse with 15 mL for 30 seconds twice daily after brushing, then expectorate. The product is not intended to be swallowed. The label also states that use in pediatric patients under 18 years has not been established.[1]

What safety issues affect excipient strategy?

The principal product-related issues are:

• Brown staining of teeth, restorations, and oral surfaces.
• Increased calculus formation.
• Altered taste perception.
• Oral irritation or hypersensitivity.
• Accidental ingestion risk.
• Alcohol sensitivity or avoidance.
• Packaging and dispensing controls for a prescription rinse.

Chlorhexidine itself contributes to staining and taste disturbance. Excipients cannot eliminate those pharmacologic effects, but improved flavor systems, lower harshness, optimized wetting, and controlled dosing can reduce treatment dissatisfaction.

When does Peridex lose exclusivity?

Peridex’s original small-molecule patent and regulatory exclusivity periods have expired. The product is not protected by biologic exclusivity, and biosimilar risk is not relevant because chlorhexidine gluconate is a chemically defined small molecule.

A current commercial assessment should distinguish three categories:

Exclusivity category	Peridex position
New chemical entity exclusivity	Expired
Original product patent protection	Expired or no longer commercially controlling
Active Orange Book formulation or method-of-use patents	No material barrier is identified from the core Peridex label and established generic market position
Biosimilar protection	Not applicable
Regulatory exclusivity for the active ingredient	Expired

Peridex therefore competes primarily through FDA approval, product quality, dental distribution, flavor acceptance, supply reliability, and brand recognition.

What patents protect Peridex and its formulation?

The commercial value of Peridex is unlikely to depend on an active foundational patent estate. Historical patents covering chlorhexidine, oral antimicrobial use, or early formulations would generally have expired before the current generic market matured.

A developer should not assume that a reformulated Peridex product is free of patent risk merely because the original product is old. Risk can arise from:

• Later patents covering a specific alcohol-free formulation.
• Flavor or taste-masking systems.
• Low-staining combinations.
• Unit-dose or metered dispensing systems.
• Mucoadhesive delivery.
• Combination oral-care products.
• Specific manufacturing processes.
• Device-and-formulation combinations.
• Private-label or branded reformulations filed after the original Peridex product.

Are there Paragraph IV risks for Peridex generics?

A Paragraph IV challenge is unlikely to be the principal entry mechanism for a legacy product with expired foundational protection and an established generic market. An ANDA applicant would normally assess any listed patents in the FDA Orange Book and certify that relevant patents are expired, invalid, unenforceable, or not infringed.

For a new formulation, the risk profile changes. A company seeking to market an alcohol-free or taste-improved product may face patents covering the reformulated product rather than the original Peridex composition. A Paragraph IV strategy could be relevant against those later patents, but the value depends on claim breadth, filing date, continuity, prosecution history, and actual market penetration.

What excipient changes create the strongest commercial opportunities?

Alcohol-free chlorhexidine rinse

An alcohol-free formulation is the clearest excipient-led opportunity. It could target patients who avoid alcohol-containing oral rinses, individuals with oral irritation, institutional purchasers with alcohol restrictions, and dental practices seeking a more tolerable product.

Removing alcohol can affect:

• Solubilization of flavor oils.
• Antimicrobial performance.
• Preservative requirements.
• Viscosity and mouthfeel.
• Flavor release.
• Microbial control during shelf life.
• Container compatibility.

PEG-40 sorbitan derivatives, polysorbates, glycerin, propylene glycol, and other solubilization systems may be evaluated, but each change requires compatibility and performance testing. A substitute surfactant can alter chlorhexidine availability or increase foaming.

Low-sting and improved sensory profile

Flavor and sweetener optimization can improve adherence. Candidates may include combinations of non-cariogenic sweeteners, high-intensity sweeteners, cooling agents, and lower-irritation flavor systems.

A successful formulation must avoid:

• Excessive bitterness aftertaste.
• Strong alcohol burn.
• Excessive menthol or cooling.
• Interactions with chlorhexidine.
• Increased staining.
• Increased microbial growth risk.
• Sensory incompatibility with dental patients.

Flavor systems are commercially attractive because they can produce a differentiated product without changing the active ingredient. Their patentability may be stronger when combined with a defined chlorhexidine concentration, solvent system, and measurable sensory or stability result.

Reduced-staining formulation

Staining is a recognized limitation of chlorhexidine therapy. A formulation could seek to reduce staining through changes in pH, surfactant selection, excipient purity, oral-surface deposition, or co-formulated anti-staining agents.

This area has higher technical and regulatory risk. A product cannot imply that it eliminates chlorhexidine staining unless supported by clinical evidence. An anti-staining excipient could also reduce chlorhexidine’s oral retention or antimicrobial activity.

Preservative-minimized or preservative-free formulation

The labeled alcohol content may contribute to microbial control, but it should not automatically be treated as the sole preservative strategy. An alcohol-free product may require a validated preservative system, microbial challenge data, improved container closure, or single-use packaging.

A preservative-free unit-dose product could target:

• Hospitals and dental clinics.
• Long-term-care facilities.
• Surgical or periodontal procedural kits.
• Patients with sensitivity to common preservatives.
• Institutional settings requiring controlled dispensing.

The manufacturing cost would be higher than for a conventional multidose bottle. The opportunity depends on whether procurement customers value reduced contamination risk enough to accept higher packaging costs.

What formulations could compete with Peridex?

Product concept	Primary excipient strategy	Target customer	Main barrier
Alcohol-free 0.12% chlorhexidine rinse	Replace alcohol with optimized solubilizer and humectant system	Alcohol-avoidant patients and dental practices	Stability, antimicrobial equivalence, taste
Low-sting rinse	Glycerin, flavor, sweetener, and solvent optimization	General dental market	Chlorhexidine bitterness and irritation
Unit-dose rinse	Aseptic or controlled-fill single-use packaging	Clinics, hospitals, institutions	Cost and packaging validation
Low-staining rinse	Modified vehicle or anti-staining co-formulant	Long-duration users	Need for clinical substantiation
Concentrate for professional dilution	Reduced packaging volume and controlled dilution	Dental offices and institutional buyers	Dosing error and regulatory complexity
Mucoadhesive rinse or gel	Polymer-based retention system	Periodontal and specialty dental use	Changed exposure, tolerability, and product classification
Chlorhexidine oral-care combination	Co-formulation with fluoride or anti-staining agent	Premium dental and specialty channels	Compatibility and clinical positioning

The most commercially realistic near-term products are alcohol-free and sensory-improved rinses. Mucoadhesive and combination products offer higher differentiation but also create greater clinical, regulatory, and intellectual-property risk.

How does Peridex compare with competing chlorhexidine products?

Peridex competes with generic chlorhexidine gluconate oral rinses, dental-office products, and consumer oral-care products containing different concentrations or active ingredients. Generic 0.12% chlorhexidine products are usually the closest substitutes because they can compete on price and prescribing familiarity.

Attribute	Peridex	Generic chlorhexidine rinse	Consumer antiseptic mouthwash
Active ingredient	Chlorhexidine gluconate 0.12%	Usually chlorhexidine gluconate 0.12%	Often essential oils, cetylpyridinium chloride, or other actives
Regulatory status	Prescription	Prescription generic	Usually nonprescription
Main use	Gingivitis management between dental visits	Same labeled use	General oral hygiene and plaque control
Alcohol profile	Labeled formulation contains alcohol	Varies by product	Varies widely
Patent barrier	Low for original product	Low	Depends on product and formulation
Differentiation	Brand familiarity and dental-channel adoption	Price and supply	Convenience, taste, and consumer branding
Main limitation	Staining and taste alteration	Same active-ingredient limitations	Lower clinical positioning for prescribed gingivitis treatment

What FDA pathway applies to a new Peridex-like product?

A conventional 0.12% chlorhexidine oral rinse would generally be developed as a prescription drug product under an ANDA pathway if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The dosage form, route, strength, active ingredient, and labeling must align with the applicable FDA requirements.[2]

Excipient changes can affect the development strategy. A product may need a more extensive review if it changes:

• Active ingredient concentration.
• Dosage form.
• Route of administration.
• Labeling claims.
• Dosing regimen.
• Pharmacokinetic or local exposure characteristics.
• Antimicrobial performance.
• Product preservation system.
• Use population.

For a substantially reformulated product, a 505(b)(2) pathway may be more appropriate than a conventional ANDA, particularly where the applicant seeks new clinical claims or relies partly on published data and partly on new studies.

What testing is critical for excipient-led differentiation?

A robust development package should evaluate:

1. Assay and degradation products.
2. Chlorhexidine content uniformity.
3. pH and osmolality.
4. Viscosity and pourability.
5. Microbial limits and preservative effectiveness.
6. Antimicrobial activity.
7. Flavor stability.
8. Container-closure compatibility.
9. Leachables and extractables.
10. Staining and calculus effects.
11. Local tolerability.
12. Comparative clinical performance where claims require it.

The most important technical risk is that an excipient change may reduce free chlorhexidine, alter oral retention, or weaken antimicrobial activity while the assay remains within specification.

Which companies could challenge or compete with Peridex?

The competitive field includes:

• Generic prescription-drug manufacturers.
• Dental-product specialists.
• Contract manufacturers with oral-liquid capabilities.
• Consumer oral-care companies entering professional dental channels.
• Specialty firms developing alcohol-free or low-staining formulations.
• Private-label suppliers serving dental distributors.

The most credible competitors are companies with existing FDA-approved liquid oral products, dental sales infrastructure, flavor-development capabilities, and validated packaging operations. A low-cost generic can enter without major formulation innovation. A premium competitor needs a measurable advantage in tolerability, staining, packaging, or institutional handling.

What licensing opportunities exist for Peridex excipients?

Licensing opportunities are more likely to involve formulation technology than the Peridex brand itself. Potential assets include:

• Proprietary chlorhexidine solubilization systems.
• Taste-masking compositions.
• Low-staining oral delivery systems.
• Alcohol-free antimicrobial vehicles.
• Unit-dose oral-rinse packaging.
• Mucoadhesive polymers.
• Stabilized flavor systems.
• Preservative-free multidose packaging.
• Combination products with anti-caries or anti-calculus functionality.

A licensing transaction would need to allocate rights across prescription dental products, over-the-counter oral care, veterinary products, and international markets. The strongest package would include composition claims, manufacturing claims, comparative stability data, and clinical or sensory evidence.

What generic launch scenarios exist for Peridex?

Low-cost conventional generic

This is the most straightforward scenario. The product matches the reference strength and dosage form and competes through price, wholesaler access, and supply reliability. Margins are likely to compress as additional suppliers enter.

Alcohol-free branded generic

This product can command a premium if dental professionals accept the sensory and tolerability profile. The sponsor would need a clear labeling position and evidence that the excipient change does not compromise product performance.

Institutional unit-dose product

A single-use format could generate higher gross margins in clinics and hospitals. Adoption depends on packaging economics, waste reduction, contamination control, and procurement contracts.

Professional combination product

A chlorhexidine product combined with an anti-staining, fluoride, or specialty dental-care component could support higher differentiation. It would also face more complex compatibility and clinical substantiation requirements.

What is the commercial exposure and patent strength of Peridex?

Peridex’s commercial exposure is concentrated in prescription dental care and professional distribution. Publicly available product labeling does not establish current sales, revenue, market share, or manufacturer-specific profitability. Revenue should therefore be modeled from prescription volume, dental-office purchasing, generic price erosion, and channel concentration rather than from the brand name alone.

The patent estate for the original Peridex formulation is weak as a market barrier because the product is a legacy small-molecule oral rinse with established generic competition. Patent strength is higher for genuinely differentiated follow-on formulations that claim a specific excipient combination and demonstrate an unexpected result, such as improved stability, reduced staining, lower irritation, or superior taste acceptance.

Key Takeaways

• Peridex is a prescription 0.12% chlorhexidine gluconate oral rinse for gingivitis.
• Its labeled excipients include water, alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No. 1.
• The original product has limited remaining exclusivity value and faces generic competition.
• Alcohol-free delivery is the clearest formulation opportunity.
• Taste masking, low-sting performance, reduced staining, and unit-dose packaging offer additional commercial paths.
• Excipient changes must preserve chlorhexidine availability, antimicrobial activity, microbial quality, stability, and local tolerability.
• A conventional equivalent product would generally fit an ANDA strategy; materially differentiated products may require a 505(b)(2) approach.
• Follow-on patents are more likely to protect specific excipient systems, delivery formats, or manufacturing processes than the original Peridex concept.
• Biosimilar risk does not apply because chlorhexidine is a small-molecule active ingredient.
• Public product information does not provide sufficient basis for a current Peridex revenue estimate.

FAQs About Peridex Excipient and Commercial Strategy

Can alcohol be removed from Peridex without changing its regulatory profile?

Removing alcohol may be possible, but the product must be reassessed for solubility, preservation, antimicrobial performance, stability, taste, and equivalence. A major formulation change can affect the appropriate FDA development pathway.

Does glycerin reduce chlorhexidine staining?

Glycerin primarily functions as a humectant and mouthfeel modifier. It should not be treated as a validated anti-staining agent without comparative clinical evidence.

Is PEG-40 sorbitan diisostearate essential to Peridex?

The labeled formulation uses PEG-40 sorbitan diisostearate as a solubilization aid, but a competitor may investigate alternative surfactants or co-solvent systems. The substitute must maintain physical stability, flavor dispersion, chlorhexidine availability, and tolerability.

Could a Peridex follow-on product be sold over the counter?

A prescription-to-OTC transition would require appropriate FDA review, consumer-use labeling, safety evidence, and a determination that consumers can use the product safely without professional supervision. The gingivitis indication and staining risks would require careful labeling analysis.

Are dental-use chlorhexidine gels a direct substitute for Peridex?

No. A gel may provide different residence time, local exposure, dosing behavior, and clinical positioning. It may compete in periodontal or localized treatment settings but does not automatically substitute for a twice-daily oral rinse.

References

1. U.S. Food and Drug Administration. (n.d.). Peridex chlorhexidine gluconate oral rinse 0.12% prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format of abbreviated applications. FDA.